Brand Reference: Vistaril
| Metric | Verified Benchmark | Source |
|---|---|---|
| Hydroxyzine Pamoate RxNorm Concept ID | 5553 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0620 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $29.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $5.70 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $7.20 / mo | 31 Zero-PHI Verified Patient Logs |
Lipophilic piperazine H1 inverse agonist (preferential pamoate salt CNS penetration) with secondary cortical 5-HT2A antagonism and low muscarinic M1 burden—aborting acute autonomic panic surges and pruritus within 25 minutes without controlled-substance addiction risk.
Across 31 community cost disclosures for Hydroxyzine Pamoate (Vistaril), cash buyers routing around $29.00 retail markups capture a 80% discount ($5.70/mo benchmark vs $0.0620 NADAC acquisition).
Following administration (25 mg PO PRN anxiety (up to TID)), Hydroxyzine Pamoate achieves 80% oral bioavailability and 15–30 minutes acute somatic calm onset, governed by a 20 hours (metabolized to cetirizine) terminal half-life through hepatic alcohol dehydrogenase & cyp3a4 oxidation to active cetirizine (45%).
Before initiating Hydroxyzine Pamoate at 25 mg PO PRN anxiety (up to TID), clinical safety checklists rule out prolonged qtc interval (> 470 ms); first trimester pregnancy; porphyria. Logged tolerability patterns center on somnolence (34% of reports), dry mouth (16% of reports).
Across 31 verified cash-pay logs, Hydroxyzine Pamoate achieves a 82.80% Worth-It rating with out-of-pocket spend averaging $7.20/mo versus $29.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 25 mg PO PRN anxiety (up to TID) for Hydroxyzine Pamoate; monthly out-of-pocket dropped to $5.02 compared with $29.00 retail.
Completed 10 weeks on Hydroxyzine Pamoate (50 mg PO QHS sleep onset). Zero notable side effects on steady dosing.
Consistent biomarker response on 25 mg PO PRN anxiety (up to TID) Hydroxyzine Pamoate sourced via Compounding ($6.61/mo cash pay without insurance prior authorization).